At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed follicular B-cell non-Hodgkin's lymphoma
- ✓Stage III or IV disease
- ✓Grade 1 or 2 disease
- ✓Previously untreated disease
- ✕CNS lymphoma
- ✕HIV infection
- ✕Other active malignancies
- ✕Active uncontrolled infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial of Denileukin Diftitox in Combination With Rituximab in Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating denileukin diftitox and rituximab for Lymphoma. Completed, enrolled 24 participants across 165 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to cancer cells. Giving rituximab together with denileukin diftitox may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with denileukin diftitox works in treating patients with previously untreated stage III or stage IV follicular B-cell non-Hodgkin's lymphoma.